This article is more than 5 years old. Information may no longer be current.

Actavis launches generic for AstraZeneca's Pulmicort Respules

Actavis has launched its generic version of AstraZeneca’s Pulmicort Respules after a U.S. District Court judge in New Jersey denied AstraZeneca’s request for a permanent injunction and invalidated its patent, according to a company press release.

Pulmicort Respules (budesonide inhalation suspension), in 0.25 mg and 0.5 mg vials, is a maintenance medicine used to control and prevent asthma symptoms in children aged 12 months to 8 years.

The FDA approved a generic version of Pulmicort Respules to Watson Laboratories in August 2012.